Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 224,979,790 papers from all fields of science
Search
Sign In
Create Free Account
MKC 442
Known as:
MKC-442
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
emivirine
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
Synthesis and evaluation of double-prodrugs against HIV. Conjugation of D4T with 6-benzyl-1-(ethoxymethyl)-5-isopropyluracil (MKC-442, emivirine)-type reverse transcriptase inhibitors via the SATE…
Lene Petersen
,
P. T. Jørgensen
,
C. Nielsen
,
T. H. Hansen
,
J. Nielsen
,
E. Pedersen
Journal of Medicinal Chemistry
2005
Corpus ID: 6544384
This paper reports the synthesis and the antiviral activities of new double-prodrugs against HIV based on the known mixed SATE (S…
Expand
2004
2004
Synthesis of Furoannelated Analogues of Emivirine (MKC‐442)
M. Wamberg
,
E. Pedersen
,
C. Nielsen
Archiv der Pharmazie
2004
Corpus ID: 35386586
Furoannelated analogues 1‐alkoxymethyl‐7‐phenyl‐5, 7‐dihydro‐1H‐furo[3, 4‐d]‐pyrimidine‐2, 4‐diones of Emivirine (3a, b) were…
Expand
2003
2003
Synthesis of Novel MKC‐442 Analogues with Potent Activities against HIV‐1
N. El‐Brollosy
,
E. Pedersen
,
C. Nielsen
Archiv der Pharmazie
2003
Corpus ID: 43897852
Bis(alken‐1‐yloxy)methanes 2 were synthesized by reacting 2‐cyclohexenol, 3‐cyclohexenylmethanol, cinnamyl alcohol and its…
Expand
2003
2003
Synthesis and evaluation of new potential HIV-1 non-nucleoside reverse transcriptase inhibitors. New analogues of MKC-442 containing Michael acceptors in the C-6 position.
Lene Petersen
,
Carsten H. Jessen
,
E. Pedersen
,
C. Nielsen
Organic and biomolecular chemistry
2003
Corpus ID: 40122772
Analogues of MKC-442 capable of undergoing Michael addition reactions were synthesised in order to investigate the activity…
Expand
2001
2001
Synthesis of nucleoside analogs and new Tat protein inhibitors
A. Ané
,
G. Prestat
,
+6 authors
D. Dubreuil
2001
Corpus ID: 8109943
Two studies, concerning the synthesis of original nucleoside analogs regarded as an application of heterochemistry on…
Expand
2000
2000
Safety Assessment, In Vitro and In Vivo, and Pharmacokinetics of Emivirine, a Potent and Selective Nonnucleoside Reverse Transcriptase Inhibitor of Human Immunodeficiency Virus Type 1
G. Szczech
,
P. Furman
,
+9 authors
CP Moxham
Antimicrobial Agents and Chemotherapy
2000
Corpus ID: 26907271
ABSTRACT Emivirine (EMV), formerly known as MKC-442, is 6-benzyl-1-(ethoxymethyl)-5-isopropyl-uracil, a novel nonnucleoside…
Expand
1999
1999
N-[2-(1-cyclohexenyl)ethyl]-N'-[2-(5-bromopyridyl)]-thiourea and N'-[2-(1-cyclohexenyl)ethyl]-N'-[2-(5-chloropyridyl)]-thiourea as potent inhibitors of multidrug-resistant human immunodeficiency…
F. Uckun
,
C. Mao
,
+4 authors
T. Venkatachalam
Bioorganic & Medicinal Chemistry Letters
1999
Corpus ID: 9319754
1999
1999
N'-[2-(2-thiophene)ethyl]-N'-[2-(5-bromopyridyl)] thiourea as a potent inhibitor of NNI-resistant and multidrug-resistant human immunodeficiency virus-1.
F. Uckun
,
S. Pendergrass
,
+4 authors
T. Venkatachalam
Bioorganic & Medicinal Chemistry Letters
1999
Corpus ID: 20711884
1997
1997
Three‐drug combination of MKC‐442, lamivudine and zidovudine in vitro: potential approach towards effective chemotherapy against HIV‐1
G. Piras
,
Kouji Nakade
,
S. Yuasa
,
M. Baba
AIDS (London)
1997
Corpus ID: 31508219
Objectives:MKC-442 (6-benzyl-1-ethoxymethyl-5-isopropyluracil), a potent non-nucleoside reverse transcriptase inhibitor, is a…
Expand
1995
1995
The inhibition of human immunodeficiency virus type 1 in vitro by a non-nucleoside reverse transcriptase inhibitor MKC-442, alone and in combination with other anti-HIV compounds.
T. Brennan
,
D. Taylor
,
C. Bridges
,
J. P. Leyda
,
A. Tyms
Antiviral Research
1995
Corpus ID: 23939626
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE